Combination therapy for malaria: The way forward?

Drugs

Volumn 62, Issue 9, 2002, Pages 1315-1329

  Nosten, François ^a,b,c   Brasseur, Philippe ^d  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISIN DERIVATIVE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; BIGUANIDE DERIVATIVE; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; ENZYME INHIBITOR; FANSIDAR; HALOFANTRINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRONARIDINE; QUININE; QUINOLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; DRUG ABSORPTION; DRUG COST; EARLY DIAGNOSIS; FINANCIAL MANAGEMENT; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MALARIA CONTROL; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; POINT MUTATION; REVIEW; TROPICS; TUBERCULOSIS;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA;

CINCHONA PUBESCENS; HUMAN IMMUNODEFICIENCY VIRUS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0036078913     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00003     Document Type: Review

References (101)

1. Current status of malaria and potential for control
2. Global warming. If the mercury soars, so may health hazards [news]
3. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia
4. Serial studies on the evolution of chloroquine resistance in an area of East Africa receiving intermittent malaria chemosuppression
5. Malaria disaster in Africa
6. Averting a malaria disaster
7. World malaria situation in 1993, part I
8. Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive use of artesunate-mefloquine
9. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study
10. Drug resistant falciparum malaria: Clinical consequences and strategies for prevention
11. Evidence that a point mutation in dihydrofolate reductase- thymidylate synthase confers resistance to pyrimethamine in falciparum malaria
12. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthetase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
13. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site
14. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites
15. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand
16. Several alleles of the multidrug resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum
17. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
18. A molecular marker for chloroquine-resistant falciparum malaria
19. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
20. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand
21. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
22. Mating patterns in malaria parasite populations of Papua New Guinea
23. Mefloquine-resistant falciparum malaria on the Thai-Burmese border
24. Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: Early treatment failure aggravates anaemia
25. Impact of chloroquine resistance on malaria mortality
26. Chloroquine-resistant Plasmodium falciparum from East Africa: Cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist
27. Decline in sensitivity of Plasmodium falciparum to chloroquine in The Gambia
28. The efficacy of pyrimethamine-sulfadoxine (Fansidar) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children
29. Multi-drug resistant falciparum malaria in Cameroon in 1987-1988. I. Stable figures of prevalence of chloroquine- and quinine-resistant isolates in the original foci
30. Emergence of mefloquine-resistant malaria in Africa without drug pressure
31. Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations
32. Status of Plasmodium falciparum resistance to chloroquine in Orissa
33. Resistance of falciparum malaria to chloroquine and sulfadoxine- pyrimethamine in Afghan refugee settlements in western Pakistan: Surveys by the general health services using a simplified in vivo test
34. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria
35. Plasmodium falciparum: Sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar
36. Management of multiple drug-resistant malaria in Viet Nam
37. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria
38. In vivo and in vitro Plasmodium falciparum resistance to chloroquine, amodiaquine and quinine in the Brazilian Amazon
39. Malaria reemergence in the Peruvian Amazon region
40. RIII mefloquine resistance in children with falciparum malaria in manaus, AM, brazil
41. In vivo efficacy of mefloquine for the treatment of Falciparum malaria in Brazil
42. Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia
43. The problem of drug resistance in malaria
44. The efficacy of short-course chemotherapy for tuberculosis
45. Antiretroviral therapy: 'The state of the art'
46. Preventing antimalarial drug resistance through combinations
47. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination
48. Effects of artemisinin derivatives on malaria transmissibility
49. Poor gametocytocidal activity of 45 mg primaquine in chloroquine- treated patients with acute, uncomplicated, Plasmodium falciparum malaria in Mumbai (Bombay): An issue of public-health importance
50. Antimalarial drug resistance and combination therapy
51. Critical issues in the economic evaluation of interventions against communicable diseases
52. Changing home treatment of childhood malaria fevers by training shop keepers in rural Kenya
53. Malaria diagnosis and treatment administered by teachers in primary schools in Tanzania
54. Teaching mothers to provide home treatment of malaria in Tigray, Ethipia: A randomised trial
55. Effect of large-scale social marketing of insecticide-treated nets on child survival in rural Tanzania
56. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: A randomised, placebo-controlled trial
57. Malaria: Living with drug resistance
58. Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission
59. Diagnosic accuracy and case management of clinical malaria in the primary health services of a rural area in south-eastern Tanzania
60. Paracheck-Pf: A new, inexpensive and reliable rapid test for P. falciparum malaria
61. Economics and its contribution to the fight against malaria
62. Fake artesunate in Southeast Asia
63. Combination therapy for malaria in Africa: Hype or hope?
64. Antimalarial drug combination policy: A caveat
65. Artemisinin antimalarials in pregnancy: A prospective treatment study of 539 multidrug-resistant P. falciparum episodes
66. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria
67. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives
68. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients
69. Monitoring the response of malaria infections to treatment
70. Malaria epidemic in Burundi
71. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: A double-blind, randomised, controlled trial
72. Treatment of Plasmodium falciparum malaria with pyrimethamine- sulfadoxine: Selective pressure for resistance is a function of long elimination half-life
73. The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector
74. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria
75. Chlorproguanildapsone for uncomplicated malaria in young children: Pharmacokinetics and therapeutic range
76. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
77. The efficacy of antifolate combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
78. Predictors of mefloquine treatment failure: A prospective study of 1590 patients with uncomplicated falciparum malaria
79. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria
80. Synthesis of 7351, a new antimalarial drug
81. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children
82. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand
83. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine
84. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs
85. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon
86. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa
87. Effects of piperaquine on the fine structure of the erythrocytic stages of Plasmodium berghei ANKA strain
88. Sensitivity of Plasmodium falciparum to seven antimalarials in China- Laos border
89. Qinghaosu
90. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae
91. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria
92. Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania
93. Donnor responsibilities in rolling back malaria
94. European Union's research policy: A moving target?